The aryl hydrocarbon receptor is required for induction of p21(cip1/waf1) expression and growth inhibition by SU5416 in hepatoma cells

The aryl hydrocarbon receptor (AhR) is a potential clinical target for cancer and autoimmune dysfunction. Identifying selective AhR modulators that produce desirable clinical outcomes represents an opportunity for developing new anti-cancer agents. Repurposing clinically-used drugs with established...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Donnell, Edmond F., Jang, Hyo Sang, Pearce, Martin, Kerkvliet, Nancy I, Kolluri, Siva Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421923/
https://www.ncbi.nlm.nih.gov/pubmed/28424418
http://dx.doi.org/10.18632/oncotarget.16056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421923/
https://www.ncbi.nlm.nih.gov/pubmed/28424418
http://dx.doi.org/10.18632/oncotarget.16056

Ejemplares similares